The ROC curve for TYROBP discrimination of survival status had an AUC of 0.674 and 0.625 based on TARGET-osteosarcoma and GSE21257 data, respectively, indicating that TYROBP was a reliable biomarker for distinguishing the survival status of osteosarcoma patients. Here, TYROBP is linked to osteosarcoma.